Related Topics >> pipeline | RNAi | sirna

SPOTLIGHT: Sirna pushing RNAi field

August 15, 2006 — 8:01pm ET

CytRx spins off RNAi assets into new company
Novartis targets biotech drugs as it boosts R&D
Nastech expands RNAi pipeline with acquisition
ALSO NOTED: Cephalon reports pain data; Sirna, GSK expand collaboration; and much more...
Alnylam wins $23M biodefense contract
Acquisition deals in biotech keep getting richer
Senetek, Nastech strike deals for RNAi technology
A billion-dollar lesson in RNAi economics
Is Alnylam Roche's 'second Genentech'?
Silence shouts about $400M AstraZeneca deal

Tools

Email
Print
Contact Author

The Motley Fool assess Sirna's chances at developing its pipeline of RNAi therapeutics. Working to control disease at the genetic level is slow going at the discovery stage, but the potential impact is enormous. Article

Paid Research Reports

RNA therapy: the next big thing after monoclonal antibodies?
Biotech M&A Strategies: Deal assessments, trends and future prospects
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
Sales Force Effectiveness
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

More Research Reports >>

Most Popular Stories

Featured Jobs

Webinars

Popular Topics

Events

SPOTLIGHT: Sirna pushing RNAi field

Related Stories

Paid Research Reports

THE FIERCEMARKETS NETWORK